Zeaxanthin Supplementation for Visual Performance in Athletes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective treatments and pharmaceutical compositions that utilize Xanthophyll carotenoids to improve visual performance and neural efficiency, particularly for athletes engaging in outdoor sports who require enhanced visual and motor skills under challenging lighting conditions.
Innovation Solution
Administration of a pharmaceutically effective amount of Zeaxanthin, either topically through an ocular solution or systemically via a solid or liquid dosage form, to increase macular pigment optical density, thereby enhancing reaction time and coincidence anticipation ability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If athletes engage in outdoor sports under challenging lighting conditions, then visual and motor performance is required at high speed, but visual function degrades due to environmental and lighting stressors
Solution Approach 1:
The patent applies preliminary action by administering xanthophyll carotenoids (lutein and zeaxanthin) before outdoor sports activities to pre-build macular pigment optical density (MPOD). This preparatory supplementation ensures that the retina is protected and visual function is optimized before exposure to challenging lighting conditions, allowing athletes to maintain high-speed visual and motor performance without degradation from environmental stressors.
2Reliability
If macular pigment optical density is increased to protect against actinic damage and oxidative stress, then visual function is improved, but no effective pharmaceutical compositions currently exist to achieve this
Solution Approach 1:
The patent applies parameter changes by formulating specific pharmaceutical compositions with defined ratios and amounts of xanthophyll carotenoids (lutein and zeaxanthin). The composition parameters are optimized to achieve effective MPOD increase, and the formulation parameters (dosage, administration route) are adjusted to ensure effectiveness while addressing the lack of available pharmaceutical products.
3Reliability
If short-wave light absorption is enhanced to improve visual performance in short-wave dominant conditions, then visual function is improved, but light scattering in the atmosphere and within the eyes degrades vision
Solution Approach 1:
The patent applies the blessing in disguise principle by using xanthophyll carotenoids to absorb the harmful short-wave light that scatters in the atmosphere and within the eye. The macular pigment converts the potentially harmful short-wave radiation into a beneficial effect by filtering it before it reaches the sensitive retinal tissue, thereby improving visual function in short-wave dominant conditions while eliminating the degradation caused by light scattering.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The supplementation with Zeaxanthin leads to significant improvements in visual performance and neural efficiency, including increased macular pigment optical density, reduced photostress recovery time, and enhanced reaction times, particularly beneficial for athletes performing under detrimental lighting conditions.
Implementation Method 1
L and Z absorb short-wave light, and because short-wave light scatters readily in the atmosphere and within the eyes, MP's ability to absorb short-wave light improves visual performance in short-wave dominant viewing conditions
Implementation Method 2
L and Z are pigments that both absorb damaging short-wave 'blue' light and serve as antioxidants, MP may be able to improve visual function by preventing acquired ocular diseases that degrade vision
Data Source
Figure 1
Figure 1A~2A
Figure 1B~2B
AI summary
In one embodiment, the invention provides a method of enhancing a subject's macular pigment optical density, the method comprising administering to the subject a pharmaceutically effective amount of one or more Xanthophyll carotenoids. Preferably, the Xanthophyll carotenoids are selected from the group consisting of lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ), and enantiomers, metabolites, esters, pharmaceutically acceptable salts and derivatives thereof. In certain embodiments, the Xanthophyll carotenoids such as lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ) are each in substantially pure enantiomeric form.